• 1. Basic Medical College, Air Force Medical University, Xi'an, 710032, P. R. China;
  • 2. Department of Thoracic Surgery, Tangdu Hospital, Air Force Medical University, Xi'an, 710038, P. R. China;
  • 3. Shaanxi University of Chinese Medicine, Xianyang, 712046, Shaanxi, P. R. China;
LU Qiang, Email: luqiang@fmmu.edu.cn
Export PDF Favorites Scan Get Citation

The 2025 European Lung Cancer Congress (ELCC) convened in Paris, France, centering on the optimization and innovation of immunotherapy for non-small cell lung cancer (NSCLC). Key topics at the congress included the application strategies for perioperative immunotherapy, breakthroughs in combination therapy models for advanced NSCLC, and the emerging roles of biomarkers in predicting diverse treatment outcomes. This paper integrates data from several key pivotal studies to systematically analyze the clinical value of neoadjuvant therapy within the perioperative setting, the potential of targeted combination regimens, and the challenges of managing drug resistance, thus offering new directions for clinical practice.

Citation: LIU Wen, LU Jiayu, ZHANG Xuxu, XU Xinyao, ZHANG Jipeng, LI Wei, LI Guizhen, BAO Bo, LU Qiang. Interpretation of advances in immune therapy for non-small cell lung cancer at the 2025 European Lung Cancer Congress. Chinese Journal of Clinical Thoracic and Cardiovascular Surgery, 2025, 32(8): 1063-1071. doi: 10.7507/1007-4848.202505023 Copy

Copyright © the editorial department of Chinese Journal of Clinical Thoracic and Cardiovascular Surgery of West China Medical Publisher. All rights reserved

  • Previous Article

    Expert consensus on lung transplant evaluation in patients with respiratory failure due to virus-induced pulmonary injury
  • Next Article

    Interpretation of clinical practice guideline for the diagnosis, treatment, and follow-up of early breast cancer